Prognostic significance of tumor tissue NeuGcGM3 ganglioside expression in patients receiving racotumomab immunotherapy
View/ Open
Access
info:eu-repo/semantics/openAccessAttribution 4.0 Internationalhttps://creativecommons.org/licenses/by/4.0/Date
2020Author
Üskent, NecdetAyla, Şule
Molinas Mandel, Nil
Özkan, Metin
Teomete, Mehmet
Baloğlu, Hüseyin
Aydinçer, Cenk
Yergök, Hale
Doğan, Ender
Berk, Barkın
Yazar, Aziz
Metadata
Show full item recordCitation
Üskent, N., Ayla, Ş., Molinas Mandel, N., Özkan, M., Teomete, M., Baloğlu, H. ... Yazar, A. (2020). Prognostic significance of tumor tissue NeuGcGM3 ganglioside expression in patients receiving racotumomab immunotherapy. Journal of Oncology, 2020. https://dx.doi.org/10.1155/2020/1360431Abstract
Expression ofN-glycolyl GM3 (NeuGcGM3) ganglioside was detected in the tumor specimens of patients who were on Racotumomab anti-idiotype vaccine maintenance treatment, and prognostic significance as a biomarker was investigated. No statistically significant association was observed in the multivariate analysis between overall survival and tissue NeuGcGM3 IHC levels. Although numerically there was a difference favoring less intense IHC for better prognosis, this did not reach statistical power. However, there was a strong correlation between Racotumomab doses and overall survival (OS). Mean OS of the patient with more than 10 Racotumomab application was significantly longer than the patient who had less than 10 injections (70.7 months vs. 31.1 months, p<0.001). We propose that, regardless of staining intensity, the presence of NeuGcGM3 in patient tissues might be an indicator of benefit in Racotumomab treatment.
WoS Q Kategorisi
Q2xmlui.dri2xhtml.METS-1.0.item-scopusquality
Q2Source
Journal of OncologyVolume
2020Collections
- Makale Koleksiyonu [273]
- Makale Koleksiyonu [3651]
- PubMed İndeksli Yayınlar Koleksiyonu [4050]
- Scopus İndeksli Yayınlar Koleksiyonu [6286]
- WoS İndeksli Yayınlar Koleksiyonu [6433]
The following license files are associated with this item: